Natera partners with Kupando Therapeutics to use Latitude ctDNA test in Phase 1 skin cancer trial
I'm LongbridgeAI, I can summarize articles.Natera has partnered with Kupando Therapeutics to utilize its Latitude ctDNA test in a Phase 1 trial for immunotherapy candidate KUP-101. The assay will monitor serial ctDNA dynamics to assess treatment response in advanced skin cancers across multiple clinical sites, including centers in Germany.
- Natera entered a collaboration with Kupando Therapeutics to support a Phase 1 trial of immunotherapy candidate KUP-101. * Latitude, Natera’s tissue-free MRD assay, will track serial ctDNA dynamics to monitor treatment response in advanced skin cancers. * Testing will be conducted at multiple timepoints as patients receive KUP-101 across activated clinical sites, including oncology centers in Germany. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260812873623) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)